Table 1 |
|||||||
|
Absolute intra-group differences between T1 (week 14) and T2 (week 26) together with mean relative difference for each of the variables in each group evaluated. |
|||||||
|
Variable |
Group |
Absolute mean T1 value |
Absolute mean T2 value |
Absolute mean difference T2-T1 |
Relative mean difference from T1 to T2 (%) |
Standard deviation (%) |
Statistical significance for growth between T1 and T2 |
|
|
|||||||
|
Angle 1 |
A |
155.3 |
156.6 |
1.3 |
0.84 |
1.7 |
n.s. |
|
B |
155.8 |
156.4 |
0.6 |
0.4 |
2.9 |
n.s. |
|
|
C |
153.9 |
154.1 |
0.2 |
0.1 |
1.6 |
n.s. |
|
|
Angle 2 |
A |
136.1 |
133.8 |
-2.3 |
-1.7 |
2.2 |
* |
|
B |
136.2 |
135.1 |
-1.1 |
-0.7 |
5.2 |
n.s. |
|
|
C |
138.7 |
137.4 |
-1.3 |
-1 |
2.2 |
n.s. |
|
|
Angle 3 |
A |
108.3 |
109.3 |
1 |
0.9 |
1.2 |
* |
|
B |
107.3 |
108.6 |
1.3 |
1.3 |
1.5 |
* |
|
|
C |
108.3 |
109.6 |
1.3 |
1.2 |
1.3 |
* |
|
|
|
|||||||
|
Sagittal (mm) |
|||||||
|
|
|||||||
|
TML |
A |
61.5 |
66.6 |
5.1 |
8.3 |
2.1 |
* |
|
(Cm-ImpB) |
B |
60.7 |
65.8 |
5.1 |
8.4 |
1.9 |
* |
|
C |
60.8 |
66.2 |
5.4 |
8.8 |
1.8 |
* |
|
|
ML1 |
A |
36.2 |
38.1 |
1.9 |
5 |
2.4 |
* |
|
(Go-ImpB) |
B |
36.5 |
38.2 |
1.7 |
4.6 |
2.5 |
* |
|
C |
35.9 |
37.6 |
2 |
5 |
2.1 |
* |
|
|
ML2 |
A |
55.6 |
59.7 |
4.1 |
7.3 |
1.7 |
* |
|
(Ar1-ImpB) |
B |
55.3 |
59.0 |
3.7 |
7.2 |
2.2 |
* |
|
C |
54.8 |
58.7 |
3.9 |
7.2 |
2.6 |
* |
|
|
ML3 |
A |
58.6 |
63.3 |
4.7 |
8 |
1.8 |
* |
|
(Ar2-ImpB) |
B |
58.6 |
63.1 |
4.5 |
7.7 |
0.9 |
* |
|
C |
58.3 |
62.8 |
4.5 |
7.7 |
1.4 |
* |
|
|
ID |
A |
15.1 |
15.5 |
0.4 |
3 |
6.2 |
n.s. |
|
(impA-impB) |
B |
14.8 |
15.1 |
0.3 |
2.7 |
5.8 |
n.s. |
|
C |
14.1 |
14.0 |
-0.1 |
-1.3 |
8.1 |
n.s. |
|
|
|
|||||||
|
Vertical (mm) |
|||||||
|
|
|||||||
|
TPMH |
A |
44.2 |
48.8 |
4.6 |
10.4 |
1.5 |
* |
|
(CmR-GoR) |
B |
43.3 |
47.9 |
4.6 |
10.8 |
1.9 |
* |
|
C |
43.5 |
49.0 |
5.5 |
12.6 |
1.7 |
* |
|
|
CMH1 |
A |
21.4 |
23.7 |
2.3 |
10.7 |
1.1 |
* |
|
(CmR-Ar1) |
B |
21.1 |
23.2 |
2.1 |
9.9 |
3.5 |
* |
|
C |
21.3 |
23.6 |
2.3 |
10.8 |
2.6 |
* |
|
|
CMH2 |
A |
22.3 |
24.3 |
2 |
8.9 |
2.0 |
* |
|
(CmR-Ar2) |
B |
22.2 |
24.3 |
2.1 |
9.4 |
2.9 |
* |
|
C |
22.1 |
24.4 |
3.3 |
10.0 |
2.3 |
* |
|
|
RH1 |
A |
27.4 |
30.3 |
2.9 |
10.7 |
2.5 |
* |
|
(Ar1-GoR) |
B |
26.8 |
29.7 |
2.9 |
11.0 |
2.3 |
* |
|
C |
26.8 |
29.9 |
3.1 |
11.6 |
3.5 |
* |
|
|
RH2 |
A |
29.5 |
32.9 |
3.4 |
11.9 |
3.4 |
* |
|
(Ar2-GoR) |
B |
28.9 |
32.5 |
3.6 |
12.3 |
2.5 |
* |
|
C |
29.2 |
32.9 |
3.7 |
12.7 |
2.7 |
* |
|
|
MBH1 |
A |
12.5 |
13.8 |
1.3 |
10.4 |
13.9 |
* |
|
(IncR⊥IL) |
B |
12.7 |
13.4 |
0.7 |
6.91 |
16.3 |
* |
|
C |
12.3 |
13.6 |
1.3 |
12.1 |
12.4 |
* |
|
|
MBH2 |
A |
18.3 |
20.5 |
2.2 |
12.2 |
3.7 |
* |
|
(MolR⊥IL) |
B |
17.9 |
19.8 |
1.9 |
11.1 |
2.9 |
* |
|
C |
17.7 |
20.2 |
2.5 |
14.1 |
3.9 |
* |
|
|
DAH |
A |
7.5 |
8.2 |
0.7 |
8.9 |
10.6 |
* |
|
(MolR⊥ML) |
B |
7.3 |
7.9 |
0.6 |
8.8 |
14.4 |
n.s. |
|
C |
7.7 |
8.7 |
1 |
12.6 |
8.4 |
* |
|
|
ANH |
A |
2.9 |
3.4 |
0.5 |
17.2 |
18.2 |
* |
|
(IncR⊥ML) |
B |
2.9 |
3.4 |
0.5 |
17.2 |
26.9 |
* |
|
C |
2.6 |
2.9 |
0.3 |
11.5 |
35.3 |
* |
|
|
|
|||||||
|
Transverse (mm) |
|||||||
|
|
|||||||
|
GD |
A |
28.1 |
29.6 |
1.5 |
5.5 |
2.8 |
* |
|
(GoR-GoL) |
B |
29.0 |
30.1 |
1.1 |
3.9 |
2.0 |
* |
|
C |
28.4 |
29.9 |
1.5 |
5.5 |
2.5 |
* |
|
|
CD |
A |
33.4 |
34.7 |
1.3 |
4.3 |
2.4 |
* |
|
(CmR-CmL) |
B |
32.5 |
33.9 |
1.4 |
4.5 |
2.2 |
* |
|
C |
33.2 |
34.4 |
1.2 |
3.7 |
1.3 |
* |
|
|
|
|||||||
|
*P < 0.05 Angles (degrees) Groups: A) placebo, B) IA etanercept, C) systemic etanercept. See figures 3, 4 and 5 for a description of the variables. |
|||||||
|
Stoustrup et al. Pediatric Rheumatology 2009 7:6 doi:10.1186/1546-0096-7-6 |
|||||||
